Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outset Medical (OM) Total Debt (2019 - 2025)

Outset Medical (OM) has disclosed Total Debt for 7 consecutive years, with $96.2 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 51.24% to $96.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.2 million through Dec 2025, down 51.24% year-over-year, with the annual reading at $96.2 million for FY2025, 51.24% down from the prior year.
  • Total Debt for Q4 2025 was $96.2 million at Outset Medical, up from $95.5 million in the prior quarter.
  • The five-year high for Total Debt was $197.4 million in Q4 2024, with the low at $29.7 million in Q1 2021.
  • Average Total Debt over 5 years is $94.7 million, with a median of $95.9 million recorded in 2025.
  • The sharpest move saw Total Debt skyrocketed 224.47% in 2023, then tumbled 52.18% in 2025.
  • Over 5 years, Total Debt stood at $29.8 million in 2021, then skyrocketed by 223.69% to $96.3 million in 2022, then soared by 35.06% to $130.1 million in 2023, then surged by 51.7% to $197.4 million in 2024, then crashed by 51.24% to $96.2 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $96.2 million, $95.5 million, and $94.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.